Metropolis Healt
Metropolis Healt Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #21 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years. Metropolis aims for volume-led growth driven by expansion in Tier 2 and Tier 3 towns, specialty testing, and TruHealth services.
From Metropolis Healt's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years.
- East India currently 6%, with limited investment so far; future investments may increase contribution.
- Overall revenue growth is volume-driven, with expansion focused on Tier 2 and Tier 3 towns through increased centers without adding more labs, improving penetration and customer reach.
- Specialty and genomics segments are key growth drivers, expecting disproportionate growth due to hospital expansions in Tier 2/3 towns.
- Addition of 1,000 more centers in 3 years planned, including 100 mini hubs offering radiology and allied services, enhancing service portfolio and customer engagement.
- TruHealth wellness portfolio to grow from 18% to 25% contribution.
- Home collection services (~11-12% revenue) have substantial growth potential.
2 more points from Metropolis Healt's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Metropolis Healt said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Metropolis is evaluating two models for radiology center expansion: capex and opex.
- If investing via capex, the approximate cost per center is INR 35-40 lakhs for equipment like X-ray, ultrasound, treadmill, DEXA scan.
- Plan to experiment with 50 centers in the first year, followed by another 50 next year, focusing on location and service quality.
- The business prioritizes disciplined capital allocation with a capital-light approach overall.
- Ongoing reinvestments in technology, digital automation, AI, and expansion of labs and centers ensure long-term relevance and growth.
- They are investing in allied healthcare services and specialty portfolios, possibly via asset-light models and subscription programs.
2 more points from Metropolis Healt's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Metropolis Healt said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Metropolis Healt said on order book & pipeline — free account, 30 seconds.
Metropolis Healt — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹450 Cr, net profit ₹57 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Metropolis Healt's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Healthcare Services this season
- Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Metropolis Healt and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Metropolis Healt Q1 FY27 results?
North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years. Metropolis aims for volume-led growth driven by expansion in Tier 2 and Tier 3 towns, specialty testing, and TruHealth services.
What is Metropolis Healt share price analysis?
Metropolis Healt currently shows a below-average growth signal. The stock trades at a P/E of 52.9 with a market cap of ₹11,002 Cr. Investors should review the full earnings analysis for detailed insights.
Is Metropolis Healt planning capital expenditure?
Metropolis is evaluating two models for radiology center expansion: capex and opex.
Keep Metropolis Healt on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.